Ingevity Corp has a consensus price target of $62.67 based on the ratings of 6 analysts. The high is $92 issued by Loop Capital on March 24, 2023. The low is $48 issued by Wells Fargo on July 14, 2025. The 3 most-recent analyst ratings were released by BMO Capital, BMO Capital, and Wells Fargo on September 5, 2025, August 7, 2025, and July 14, 2025, respectively. With an average price target of $59.33 between BMO Capital, BMO Capital, and Wells Fargo, there's an implied 5.95% upside for Ingevity Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/05/2025 | 21.43% | BMO Capital | $62 → $68 | Maintains | Outperform | |||
08/07/2025 | 10.71% | BMO Capital | $56 → $62 | Maintains | Outperform | |||
07/14/2025 | -14.29% | Wells Fargo | $38 → $48 | Maintains | Equal-Weight | |||
05/07/2025 | -32.14% | Wells Fargo | $32 → $38 | Maintains | Equal-Weight | |||
04/09/2025 | -42.86% | Wells Fargo | $45 → $32 | Maintains | Equal-Weight | |||
02/26/2025 | 16.07% | BMO Capital | $62 → $65 | Upgrade | Market Perform → Outperform | |||
02/20/2025 | 10.71% | BMO Capital | $61 → $62 | Maintains | Market Perform | |||
10/31/2024 | -16.07% | BMO Capital | $40 → $47 | Maintains | Market Perform | |||
09/30/2024 | -28.57% | BMO Capital | $42 → $40 | Maintains | Market Perform | |||
08/05/2024 | -25% | BMO Capital | $45 → $42 | Maintains | Market Perform | |||
08/05/2024 | -28.57% | Wells Fargo | $45 → $40 | Maintains | Equal-Weight | |||
08/01/2024 | -10.71% | Oppenheimer | $58 → $50 | Maintains | Outperform | |||
07/11/2024 | -19.64% | Wells Fargo | $55 → $45 | Maintains | Equal-Weight | |||
05/08/2024 | -1.79% | BMO Capital | $50 → $55 | Maintains | Market Perform | |||
05/07/2024 | — | Loop Capital | $49 → $56 | Maintains | Hold | |||
05/02/2024 | 3.57% | Oppenheimer | $50 → $58 | Maintains | Outperform | |||
04/22/2024 | 10.71% | Jefferies | $52 → $62 | Upgrade | Hold → Buy | |||
02/23/2024 | -10.71% | Wells Fargo | $43 → $50 | Maintains | Equal-Weight | |||
11/09/2023 | -23.21% | BMO Capital | $54 → $43 | Maintains | Market Perform | |||
10/03/2023 | -5.36% | Loop Capital | $62 → $53 | Downgrade | Buy → Hold | |||
08/07/2023 | 7.14% | BMO Capital | $71 → $60 | Downgrade | Outperform → Market Perform | |||
07/27/2023 | — | Loop Capital | — | Upgrade | Hold → Buy | |||
05/23/2023 | -1.79% | Wells Fargo | $66 → $55 | Maintains | Equal-Weight | |||
05/09/2023 | 42.86% | BMO Capital | $100 → $80 | Maintains | Outperform | |||
05/05/2023 | 17.86% | Wells Fargo | $80 → $66 | Maintains | Equal-Weight | |||
05/05/2023 | 14.29% | Loop Capital | $92 → $64 | Downgrade | Buy → Hold | |||
04/17/2023 | 42.86% | Wells Fargo | $85 → $80 | Maintains | Equal-Weight | |||
03/24/2023 | 64.29% | Loop Capital | $100 → $92 | Maintains | Buy | |||
03/01/2023 | 51.79% | Wells Fargo | $76 → $85 | Maintains | Equal-Weight | |||
02/02/2023 | 78.57% | Loop Capital | $81 → $100 | Upgrade | Hold → Buy | |||
01/09/2023 | 35.71% | Wells Fargo | $73 → $76 | Maintains | Equal-Weight |
The latest price target for Ingevity (NYSE:NGVT) was reported by BMO Capital on September 5, 2025. The analyst firm set a price target for $68.00 expecting NGVT to rise to within 12 months (a possible 21.43% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Ingevity (NYSE:NGVT) was provided by BMO Capital, and Ingevity maintained their outperform rating.
The last upgrade for Ingevity Corp happened on February 26, 2025 when BMO Capital raised their price target to $65. BMO Capital previously had a market perform for Ingevity Corp.
The last downgrade for Ingevity Corp happened on October 3, 2023 when Loop Capital changed their price target from $62 to $53 for Ingevity Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ingevity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ingevity was filed on September 5, 2025 so you should expect the next rating to be made available sometime around September 5, 2026.
While ratings are subjective and will change, the latest Ingevity (NGVT) rating was a maintained with a price target of $62.00 to $68.00. The current price Ingevity (NGVT) is trading at is $56.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.